Results 231 to 240 of about 3,108,169 (356)

The 9th International RASopathies Symposium

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT The RASopathies are a group of congenital disorders with overlapping clinical manifestations that are caused by pathogenic germline or early somatic variants that result in the hyperactivation of the RAS/mitogen‐activated protein kinase (MAPK) signaling pathway.
Pau Castel, Lisa Schoyer, Beth Stronach, Raya Bogdanova, Anton M. Bennett, Jaishri Blakeley, Miriam Bornhorst, Tammy Bowers, Saskia M. Brachmann, Emma Burkitt‐Wright, Kathryn Chatfield, Alessandro De Luca, Khalil El‐Chammas, Abdul Elkadri, John E. Fortunato, Bruce D. Gelb, Anne Goriely, Karen Gripp, Kassidy Grover, Lindsay Homan, Kenneth A. Kern, Maija Kiuru, Charles (Chuck) Lawson, Yong‐Seok Lee, Frank McCormick, Gina Ney, Cristina Nuevo‐Tapioles, Sara Pardej, Elizabeth I. Pierpont, Julia Plank, Nancy Ratner, Katherine A. Rauen, J. Elliott Robinson, Les Rogers, Sarah E. Sheppard, Keir Shiels, David Stevenson, Dagmar Tiemens, Matthew Traylor, K. Nicole Weaver, Marielle Yohe, Tamar Green   +41 more
wiley   +1 more source

Fulminant Immune Checkpoint Inhibitor-Induced Myocarditis and Complete Heart Block in Advanced Melanoma: A Case Report. [PDF]

Cureus
Alhayek B, Malone X, Rashid MA, Sepulveda L, Ramsakal A.   +4 more
europepmc   +1 more source

Zebrafish and CRISPR—A synergistic approach to decipher and cure human diseases

Animal Models and Experimental Medicine, EarlyView.
Zebrafish, with high genetic homology to humans, serves as a powerful vertebrate model for disease modeling and drug discovery. Integration of CRISPR/Cas9 technology enables precise genome editing, facilitating the development of translational models for human diseases.
Manikandan Sivaprakasam, Aashika Raagavi Jeanpierre, Salma Mohammed, Rajesh Srinivasan, Aman Kumar Mohanty   +4 more
wiley   +1 more source

Efficacy and Safety of DNV3 (a Lymphocyte-activation Gene 3-blocking Antibody) Combined With Toripalimab and Chemotherapy in Advanced Melanoma: An Open-label, Single-arm Clinical Trial. [PDF]

MedComm (2020)
Lin J, Chen L, Chen L, Wang D, Lu Y, Zhang H, Chen P, Yan W, Xiao Z, Chen Y.   +9 more
europepmc   +1 more source

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

New England Journal of Medicine, 2012
J. Sosman, Kevin B. Kim, L. Schuchter, R. Gonzalez, A. Pavlick, J. Weber, G. McArthur, Thomas E. Hutson, S. Moschos, K. Flaherty, P. Hersey, R. Kefford, D. Lawrence, I. Puzanov, K. Lewis, R. Amaravadi, B. Chmielowski, H. Lawrence, Y. Shyr, Fei Ye, Jiang Li, K. Nolop, Richard J Lee, A. Joe, A. Ribas   +24 more
semanticscholar   +1 more source

Cancer therapy‐induced ototoxicity: Current challenges and emerging management strategies

Animal Models and Experimental Medicine, EarlyView.
This review comprehensively examines the key risk factors for cancer therapy‐induced ototoxicity, including cumulative drug dose, genetic susceptibility, and combined treatment regimens. It highlights current challenges in ototoxicity monitoring, such as insufficient timeliness and limited clinical adoption, and advocates for standardized auditory ...
Yuqi Huang, Baoying Xu, Xinru Chen, Yu Chen, Dehong Yu   +4 more
wiley   +1 more source

GLUT1 expression, lymphocyte distribution and CD3⁺ T-cell metabolic subsets as predictive markers of response to immunotherapy in advanced melanoma. [PDF]

J Exp Clin Cancer Res
Paver EC, Gide TN, Yaseen Z, Cornejo-Paramo P, Ferguson P, Maher NG, Menzies AM, Carlino MS, da Silva IP, Holst J, Long GV, Scolyer RA, Wilmott JS.   +12 more
europepmc   +1 more source

Humanized immune system animal models and their recent applications

Animal Models and Experimental Medicine, EarlyView.
In this review, we provide an updated and comprehensive overview of the current state of humanized immune system animal model research. We discuss the variety of techniques used to produce humanized mice with their respective strengths and weaknesses, and evaluate the advantages and limitations of these models, including issues with incomplete immune ...
Nicolas Skuli, Rudra B. Amin, A’ishah Bakayoko, Marisa Kruidenier, Sahara Aqui, Sarah J. Skuli, Terence P. Gade   +6 more
wiley   +1 more source

Germline MC1R Variant Status and Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Melanoma. [PDF]

Pigment Cell Melanoma Res
Yang M, Brage SE, Lapins J, Grozman V, Svedman FC, Höiom V, Helgadottir H.   +6 more
europepmc   +1 more source

Therapeutic Applications of Stimuli‐Based Release and Engineering of Extracellular Vesicles

Advanced NanoBiomed Research, EarlyView.
This review summarizes the effects of endogenous and exogenous stimuli, their effects on the natural release of extracellular vesicles, as well as their uptake and release. It also gives an overview of stimuli‐responsive EVs and their therapeutic applications. Extracellular vesicles (EVs), nano‐ to microsized lipid bilayer membrane‐bound particles, are
Gloria Kemunto, Kristen Dellinger
wiley   +1 more source